Breaking Ground in Cystic Fibrosis Treatment: Nabriva Therapeutics’ Xenleta (Lefamulin) Phase 1 Trial Yields Promising Results
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ:…